Humacyte Inc (HUMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Humacyte Inc (HUMA) Stock Forecast
Analysts expect Humacyte (HUMA) to earn -$0.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.64M. Of 6 analysts, 4 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.17, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 3 | 50.0% |
| Hold | 2 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 570.1%.
- Fiscal year ending Dec 31, 2026
- -$0.37
- EPS consensus, revenue $3.64M
- Fiscal year ending Dec 31, 2027
- -$0.27
- EPS consensus, revenue $24.39M
- Next report
- Mar 25, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.37 | -$0.38 to -$0.35 | 2 | $3.64M | $2.44M to $5.19M | 4 |
| Dec 31, 2027 | -$0.27 | -$0.32 to -$0.19 | 4 | $24.39M | $14.90M to $43.35M | 4 |
Quarterly Estimates
The EPS consensus is -$0.07 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.11 to -$0.05 | 8 | $2.15M | $1.96M to $2.42M | 7 |
| Mar 31, 2027 | -$0.07 | -$0.09 to -$0.05 | 3 | $2.13M | $1.23M to $3.40M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.40.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.37 | -$0.40 | -$0.40 | -$0.40 | -$0.40 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.27 | -$0.25 | -$0.25 | -$0.25 | -$0.25 | N/A |
| Quarter ending Mar 31, 2027 | -$0.07 | -$0.07 | -$0.07 | -$0.07 | -$0.08 | N/A |
Frequently Asked Questions About HUMA
What is the HUMA stock forecast?
Consensus analyst estimates put Humacyte's EPS at -$0.37 for the fiscal year ending Dec 31, 2026, on revenue of $3.64M. The consensus rating from 6 analysts is Buy.
How do analysts rate HUMA stock?
Of 6 analysts covering Humacyte, 1 rates it Strong Buy, 3 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from HUMA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.37, with estimates from -$0.38 to -$0.35 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.27, with estimates from -$0.32 to -$0.19 from 4 analysts.
What revenue do analysts expect from Humacyte next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.64M, with estimates from $2.44M to $5.19M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $24.39M, with estimates from $14.90M to $43.35M.
How many analysts cover HUMA?
6 analysts rate Humacyte stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HUMA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors